The practice of “liquid biopsy” as a diagnostic, prognostic and theranostic tool in non-small
cell lung cancer (NSCLC) patients is an appealing approach, at least in theory, since it is …

Non-small cell lung cancer (NSCLC) has the highest morbidity and mortality worldwide
among malignant tumors. NSCLC is a great threat to health and well-being. Biopsy is the …

Background: Lung cancer is a major health burden causing 160,000 and 1.6 million deaths
annually in the United States and worldwide, respectively. Methods: While seeking to …

Circulating tumor cells (CTCs) are promising biomarkers for clinical application. Cancer
screening with Low-Dose Computed Tomography (LDCT) and CTC detections in pulmonary …

Syndecan-1 is a heparan sulfate proteoglycan expressed by endothelial and epithelial cells
and involved in wound healing and tumor growth. Surface-expressed syndecan-1 …

Background Circulating tumor cells (CTCs) are frequently detected in patients with
advanced-stage malignant tumors and could act as a predictor of poor prognosis. However …

There is increasing evidence for the use of circulating tumor cells (CTCs) as a “liquid biopsy”
for early detection of lung cancer recurrence, prognosticating disease and monitoring …

Abstract Knowledge on the molecular mechanisms underlying metastasis colonization in
Non-Small Cell Lung Cancer (NSCLC) remains incomplete. A complete overview integrating …

Lung cancer stem cells are supposed to be the main drivers of tumor initiation, maintenance,
drug resistance, and relapse of the disease. Hence, identification of the cellular and …

Circulating tumor cells (CTCs) are tumor cells that are separated from the primary site or
metastatic lesion and disseminate in blood circulation. CTCs are considered to be part of the …